CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]